作者
Latifa Zekri,Nisha Prakash,Monika Engel,Timo Manz,Stefanie Müller,Jonas S. Heitmann,Sebastian Hörner,Ilona Hagelstein,Martin Pflügler,Gundram Jung,Helmut Rainer Salih
摘要
Bispecific antibodies (bsAbs) that stimulate CD3 (bsAbsCD3) have emerged as promising therapeutic compounds and effectively induce T cell responses by providing “signal 1" for T cell activation. However, the efficacy of these reagents is often limited by T cell exhaustion that is caused by excessive TCR/CD3 signaling in the absence of a costimulatory "signal 2". We recently developed a PSMAxCD3 bsAb (CC-1) and currently evaluate this bsAbCD3 in patients with metastatic, castration-resistant prostate carcinoma (NCT04104607). While treatment with CC-1 significantly reduced PSA levels in the heavily pretreated patients, the induced T cell activity as well as PSA reduction was rather transient. Using blood samples of our study patients in ex vivo analyses, we here show that T cells loose responsiveness and cytotoxic capacity over time upon exposure to PSMAxCD3 treatment. To overcome this limitation, we generated novel bispecific costimulatory antibodies for tumor-restricted activation of CD28 (BiCos) to sustain the efficacy of bsAbCD3 such as CC-1. A lead construct directed to Endoglin (BiCo-1) was identified based on producibility, minimal aggregation tendency and, most importantly, fully target cell-restricted CD28-stimulatory activity. We demonstrate in various in vitro and in vivo models that BiCo-1 alone exhibits neither therapeutic effects nor toxicity. However, in combination with bsAbCD3 including CC-1, BiCo-1 induced sustained T cell proliferation and memory formation, and profoundly increased the antitumor efficacy of bsAbCD3. Finally, and perhaps most importantly, BiCo-1 also reverted T cell exhaustion induced by CC-1 single agent treatment in patient-derived T cells ex vivo. Taken together, these data demonstrate that the combinatorial use of bsAbCD3 and Bicos may profoundly enhance the sustainability and specificity of therapeutically induced T cell responses against tumors. The GMP-compliant production of BiCo-1 as well as preclinical evaluation in non-human primates has been completed, and a first-in-human clinical trial in prostate cancer patients is will begin recruitment in 2025. Citation Format: Latifa Zekri, Nisha Prakash, Monika Engel, Timo Manz, Stefanie Müller, Jonas Heitmann, Sebastian Hörner, Ilona Hagelstein, Martin Pflügler, Gundram Jung, Helmut R. Salih. Tumor-targeted CD28 bispecific antibodies enhance the antitumor efficacy of CD3-bispecifics and mitigate T cell exhaustion [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 3797.